The New York-based drugmaker will further develop the anti-UBR5 molecules for treatment-resistant TNBC and ovarian cancers
News items for the week of July 26, 2021.
Revenues from pharmaceutical products were almost entirely driven by the COVID-19 treatment remdesivir, though sales of Kite Pharma's CAR T-cell therapies grew, too.
By sequencing dozens of locally advanced or metastatic neuroendocrine neoplasm samples, researchers detected somatic mutations that varied with primary tumor site and subtype.
In the second quarter, Blueprint reported $8.5 million in revenue from Ayvakit and $2.9 million in revenue from Gavreto.
The company's pharmaceutical revenues were led by robust sales of Keytruda, which racked up $4.18 billion during the quarter.
The firm will provide testing using its HCCscreen assay and help develop follow-up procedures as part of an effort to advance cancer early detection in rural areas of China.
The test uses next-generation sequencing to detect cancer-linked mutations in 607 genes to help guide patient treatment.
The company reported revenues of $8.22 billion, largely driven by sales of its COVID-19 vaccine, but also due to strong performance of its oncology segment.
The company will start evaluating in a Phase I trial the activity of the targeted alpha therapy FPI-1966 in FGFR3-expressing solid tumors.